High-quality, cost-effective and rapid-turnaround, GLP testing against hERG
Metrion ensures customers receive accurate and reliable data without compromising on quality
Metrion Biosciences is a leading provider of high-quality GLP (Good Laboratory Practice) hERG testing services, designed to meet the stringent needs of pharmaceutical and biotech companies involved in drug discovery. With a strong focus on delivering cost-effective solutions, Metrion ensures customers receive accurate and reliable data without compromising on quality, all within a remarkably quick turnaround time.
The hERG (human Ether-à-go-go-Related Gene) assay is a critical component in the early stages of drug discovery, and GLP hERG testing is vitally important for the Investigational New Drug (IND) process.
Robust, reproducible, and compliant data
Metrion has invested in state-of-the-art electrophysiology platforms and employs highly trained scientists to ensure the highest data quality.
The rigorous standards that Metrion adheres to guarantee that the data generated is robust, reproducible, and compliant with regulatory guidance, making it suitable for submission to regulatory authorities worldwide.
Rapid turnaround of GLP hERG testing
One of the key strengths of Metrion’s GLP hERG testing service is the rapid turnaround time. In the fast-paced world of drug discovery, delays in safety testing can slow down the entire discovery process, potentially leading to increased costs and lost opportunities. We understand this urgency and have streamlined processes to deliver GLP hERG testing results in a timeframe that supports the accelerated pace of modern drug discovery.
This speed does not come at the expense of quality; every assay is meticulously conducted, and data is rigorously analysed to ensure it meets the highest standards.
Cost efficient GLP hERG testing
Cost is another critical consideration for companies outsourcing their GLP hERG testing needs. Metrion offers a highly competitive pricing structure, making it possible for organizations of all sizes to access premium GLP hERG testing services without straining their budgets. We provide these services at competitive rates without sacrificing the quality of the data.
Customer-centric approach
Each customer receives personalized service tailored to their specific needs. Whether a single study or a series of testing over the course of a project, Metrion is equipped to provide flexible solutions that fit within the customer’s timelines and budget.
This adaptability is particularly valuable for smaller biotech firms and academic institutions, which may have more limited resources but still require high-quality data to advance their drug discovery programs.
We are committed to maintaining the highest standards of scientific excellence while ensuring our services remain accessible and affordable. By choosing Metrion for GLP hERG testing, customers can be confident that they are receiving reliable, regulatory-compliant data that will support their decision-making processes and help bring safer, more effective drugs to market faster.
Ion channel screening resource library
Publications
- Ion Channel Drug Discovery and Modern Medicine.
- Ion Channel Discovery – Partnering to Access Specialized Expertise.
- Recent advances in electrophysiology-based screening technology and the impact upon ion channel discovery research.
- Clathrodin, hymenidin and oroidin, and their synthetic analogues as inhibitors of the voltage-gated potassium channels.
- Novel K+ Channel Targets in Atrial Fibrillation Drug Development – Where Are We?
- Human Electrophysiological and Pharmacological Properties of XEN-D0101: A Novel Atrial-Selective Kv1.5/IKur Inhibitor.
Videos and Presentations
- Designing multiple assay protocols for ligand gated ion channels using the stacked-tip feature on the Patchliner and SP384i platforms
- The benefits of targeting ion channels for pain and some of the hurdles in developing successful ion channel modulators.
Posters
- Identification of Novel Scorpion Venom Peptide Inhibitors of the Kv1.3 Ion Channel and their Potential as Drug Discovery Leads for Human T-Cell Mediated Disease.
- The development of a set of novel small molecule inhibitors of the Kv1.3 ion channel.
- A drug discovery collaboration between Japanese pharma and a UK SME CRO successfully developed novel small molecule inhibitors of the Kv1.3 channel to treat autoimmune disease.
Application notes and resources
- ASIC1a Ligand Gated Ion Channel Assay (App Note)
- Investigating the correlation between thallium flux and automated patch-clamp for ion channel activators.
- Identification of novel ion-channel binders: TRPA1 antagonist case study.
- The development of a set of novel small molecule inhibitors of the Kv1.3 ion channel.
- Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells.
- A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm
- The Nav 1.5 Late Current in WT and Nav 1.5 ΔKPQ Mutant Channels: An Automated Patch Clamp LQT3 Electrophysiological Assay Comparison. Safety Pharmacology Society Virtual Meeting 2020.
- NaV1.5-ΔKPQ late INa current properties and pharmacology on the SyncroPatch 384i
- Recent advances in targeting ion channels to treat chronic pain.
- Marc Rogers (Metrion Director and Former CSO) takes part in a collaborative webinar with Nanion Technologies entitled “Validation and optimization of automated patch clamp voltage-gated Ca2+ channel assays”.
- Open access to the KCNQ channel: Retigabine and second generation M-current openers.
- Development of native and stem cell-derived electrophysiological assays for neurotoxicology screening and translational drug discovery
- Characterization of Endogenous Sodium Channels in the ND7-23 Neuroblastoma Cell Line: Implications for Use as a Heterologous Ion Channel Expression System Suitable for Automated Patch Clamp Screening.
- Optimising a difficult Nav1.8 cell line assay for automated patch clamp screening. Ion Channel Retreat, Vancouver, 2015
- Synthesis and biological evaluation of piperazine derivatives as novel isoform selective voltage-gated sodium (Nav) 1.3 channel modulators
- Action of Clathrodin and Analogues on Voltage-Gated Sodium Channels
- Novel state-dependent voltage-gated sodium channel modulators, based on marine alkaloids from Agelas sponges
- Ligand- and structure-based virtual screening for clathrodin-derived human voltage-gated sodium channel modulators
- The role of Nav1.7 in human nociceptors: insights from human induced pluripotent stem cell-derived sensory neurons of erythromelalgia patients
- Assessment of human induced pluripotent stem cell-derived cardiomyocytes for evaluating drug-induced arrhythmias with multi-electrode array
- Development of an impedance based screening assay for cardiac safety and cardiotoxicity detection in stem cell derived cardiomyocytes
- Validation of an impedance-based phenotypic screening assay able to detect multiple mechanisms of chronic cardiotoxicity in human stem cell-derived cardiomyocytes
- Electrophysiological characterisation of Cellular Dynamics International ventricular iCell2 iPSC-derived cardiomyocytes
- Functional characterisation of human iPSC-derived atrial cardiomyocytes
Let’s work together
What are your specific GLP hERG Screening requirements?
If you have any questions, or would like to discuss your project, we will put you directly in touch with a member of our scientific team. Contact us today to discover more.